PL2300474T3 - Spiro(piperydyno-4,2`-pirolidyno)-1-(3,5-trifluorometylofenylo)metylokarboksyamidy jako antagonisty receptorów tachykininowych NK1 - Google Patents

Spiro(piperydyno-4,2`-pirolidyno)-1-(3,5-trifluorometylofenylo)metylokarboksyamidy jako antagonisty receptorów tachykininowych NK1

Info

Publication number: PL2300474T3
Authority: PL; Poland
Prior art keywords: tachikynin; methylcarboxamides; spiro; pyrrolidine; piperidine
Prior art date: 2008-05-01

Application number

PL09738179T

Other languages

English (en)

Inventor

Giuseppe Alvaro

Emiliano Castiglioni

Agostino Marasco

Original Assignee

Nerre Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-01

Filing date

2009-04-29

Publication date

2013-03-29

2009-04-29 Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd

2013-03-29 Publication of PL2300474T3 publication Critical patent/PL2300474T3/pl

Links

BFAHRLVWYDSXIA-UHFFFAOYSA-N 1,8-diazaspiro[4.5]decane Chemical compound C1CCNC21CCNCC2 BFAHRLVWYDSXIA-UHFFFAOYSA-N 0.000 title 1
-1 5- trifluoromethyl phenyl Chemical group 0.000 title 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Addiction (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL09738179T 2008-05-01 2009-04-29 Spiro(piperydyno-4,2`-pirolidyno)-1-(3,5-trifluorometylofenylo)metylokarboksyamidy jako antagonisty receptorów tachykininowych NK1 PL2300474T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0808030.1A GB0808030D0 (en)	2008-05-01	2008-05-01	Novel compounds
PCT/EP2009/055190 WO2009133135A1 (en)	2008-05-01	2009-04-29	Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
EP09738179A EP2300474B1 (en)	2008-05-01	2009-04-29	Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists

Publications (1)

Publication Number	Publication Date
PL2300474T3 true PL2300474T3 (pl)	2013-03-29

Family

ID=39537192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09738179T PL2300474T3 (pl)	2008-05-01	2009-04-29	Spiro(piperydyno-4,2`-pirolidyno)-1-(3,5-trifluorometylofenylo)metylokarboksyamidy jako antagonisty receptorów tachykininowych NK1

Country Status (22)

Country	Link
US (2)	US8367692B2 (pl)
EP (1)	EP2300474B1 (pl)
JP (1)	JP5524183B2 (pl)
KR (1)	KR101645743B1 (pl)
CN (1)	CN102083832B (pl)
AU (1)	AU2009242120B2 (pl)
BR (1)	BRPI0910530B8 (pl)
CA (1)	CA2723062C (pl)
CY (1)	CY1113458T1 (pl)
DK (1)	DK2300474T3 (pl)
EA (1)	EA017960B1 (pl)
ES (1)	ES2395571T3 (pl)
GB (1)	GB0808030D0 (pl)
HR (1)	HRP20121018T1 (pl)
IL (1)	IL208917A (pl)
MX (1)	MX2010011985A (pl)
PL (1)	PL2300474T3 (pl)
PT (1)	PT2300474E (pl)
RS (1)	RS52719B (pl)
SI (1)	SI2300474T1 (pl)
WO (1)	WO2009133135A1 (pl)
ZA (1)	ZA201007519B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2484674A1 (en) *	2011-02-02	2012-08-08	Rottapharm S.P.A.	Spiro aminic compounds with NK1 antagonist activity
CN109651368A (zh) *	2018-12-17	2019-04-19	武汉药明康德新药开发有限公司	4-甲酸甲酯-2-氧-1,8-二氮杂螺[4.5]癸烷-8-甲酸叔丁酯的制备方法
CA3177477A1 (en) *	2020-06-02	2021-12-09	Nerre Therapeutics Limited	Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9215706D0 (en)	1992-07-23	1992-09-09	Tollpass Limited	Parking toll collecting system
JPH08511522A (ja) *	1993-06-07	1996-12-03	メルクエンドカンパニーインコーポレーテッド	ニューロキニンアンタゴニストとしてのスピロ置換アザ環
ATE265209T1 (de)	1996-07-17	2004-05-15	Merck & Co Inc	Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US6013652A (en) *	1997-12-04	2000-01-11	Merck & Co., Inc.	Spiro-substituted azacycles as neurokinin antagonists
WO2001030348A1 (en)	1999-10-25	2001-05-03	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
GB0203022D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
WO2003066589A1 (en) *	2002-02-08	2003-08-14	Glaxo Group Limited	Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
JP4389478B2 (ja) *	2002-05-29	2009-12-24	田辺三菱製薬株式会社	新規ピペリジン誘導体
JP4380508B2 (ja) *	2003-11-28	2009-12-09	田辺三菱製薬株式会社	医薬組成物
JP2005154380A (ja) *	2003-11-28	2005-06-16	Tanabe Seiyaku Co Ltd	ピペリジン誘導体
WO2005051912A1 (ja) *	2003-11-28	2005-06-09	Tanabe Seiyaku Co., Ltd.	ピペリジン化合物およびその製法
GB0514707D0 (en) *	2005-07-18	2005-08-24	Glaxo Group Ltd	Chemical compounds

2008
- 2008-05-01 GB GBGB0808030.1A patent/GB0808030D0/en not_active Ceased
2009
- 2009-04-29 BR BRPI0910530A patent/BRPI0910530B8/pt not_active IP Right Cessation
- 2009-04-29 CN CN2009801257867A patent/CN102083832B/zh not_active Expired - Fee Related
- 2009-04-29 EP EP09738179A patent/EP2300474B1/en active Active
- 2009-04-29 ES ES09738179T patent/ES2395571T3/es active Active
- 2009-04-29 WO PCT/EP2009/055190 patent/WO2009133135A1/en not_active Ceased
- 2009-04-29 CA CA2723062A patent/CA2723062C/en active Active
- 2009-04-29 PL PL09738179T patent/PL2300474T3/pl unknown
- 2009-04-29 KR KR1020107026865A patent/KR101645743B1/ko not_active Expired - Fee Related
- 2009-04-29 MX MX2010011985A patent/MX2010011985A/es active IP Right Grant
- 2009-04-29 HR HRP20121018AT patent/HRP20121018T1/hr unknown
- 2009-04-29 JP JP2011506703A patent/JP5524183B2/ja not_active Expired - Fee Related
- 2009-04-29 US US12/989,699 patent/US8367692B2/en not_active Expired - Fee Related
- 2009-04-29 SI SI200930430T patent/SI2300474T1/sl unknown
- 2009-04-29 AU AU2009242120A patent/AU2009242120B2/en not_active Ceased
- 2009-04-29 RS RS20120551A patent/RS52719B/sr unknown
- 2009-04-29 EA EA201071259A patent/EA017960B1/ru not_active IP Right Cessation
- 2009-04-29 PT PT97381792T patent/PT2300474E/pt unknown
- 2009-04-29 DK DK09738179.2T patent/DK2300474T3/da active
2010
- 2010-10-21 ZA ZA2010/07519A patent/ZA201007519B/en unknown
- 2010-10-25 IL IL208917A patent/IL208917A/en active IP Right Grant
2012
- 2012-11-21 US US13/682,889 patent/US8633214B2/en not_active Expired - Fee Related
- 2012-12-17 CY CY20121101226T patent/CY1113458T1/el unknown

Also Published As

Publication number	Publication date
CN102083832A (zh)	2011-06-01
IL208917A0 (en)	2011-01-31
BRPI0910530B8 (pt)	2021-05-25
JP2011518861A (ja)	2011-06-30
US20110053922A1 (en)	2011-03-03
PT2300474E (pt)	2013-01-07
US8633214B2 (en)	2014-01-21
WO2009133135A1 (en)	2009-11-05
CA2723062C (en)	2016-07-05
AU2009242120B2 (en)	2012-05-24
EP2300474A1 (en)	2011-03-30
ES2395571T3 (es)	2013-02-13
SI2300474T1 (sl)	2013-01-31
JP5524183B2 (ja)	2014-06-18
CA2723062A1 (en)	2009-11-05
KR20110015421A (ko)	2011-02-15
ZA201007519B (en)	2011-11-30
DK2300474T3 (da)	2012-12-10
CN102083832B (zh)	2013-06-05
EA201071259A1 (ru)	2011-10-31
BRPI0910530B1 (pt)	2020-02-11
US20130123250A1 (en)	2013-05-16
GB0808030D0 (en)	2008-06-11
AU2009242120A1 (en)	2009-11-05
IL208917A (en)	2014-06-30
EA017960B1 (ru)	2013-04-30
EP2300474B1 (en)	2012-10-03
CY1113458T1 (el)	2016-06-22
MX2010011985A (es)	2011-02-24
HRP20121018T1 (hr)	2013-01-31
US8367692B2 (en)	2013-02-05
BRPI0910530A2 (pt)	2015-08-18
RS52719B (sr)	2013-08-30
KR101645743B1 (ko)	2016-08-04

Publication	Publication Date	Title
IL195110A0 (en)	2009-09-22	Substituted spirocyclic cgrp receptor antagonists
AP2739A (en)	2013-09-30	Azaindazole compounds as CCRI receptor antagonists
SI2001876T1 (sl)	2011-09-30	8-azabiciklo(3.2.1)oktanske spojine kot antagonisti mu-opioidnega receptorja
ZA200702209B (en)	2008-11-26	2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
ZA200708067B (en)	2008-11-26	Spirocyclic thrombin receptor antagonists
ZA201000676B (en)	2010-10-27	Pyrrolidine aryl-ether as NK3 receptor antagonists
ZA201001125B (en)	2010-10-27	Pyrrolidine Aryl-Ether as NK3 receptor antagonists
PL2238110T3 (pl)	2012-03-30	Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
IL188478A0 (en)	2008-04-13	Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
IL190686A0 (en)	2008-11-03	Il-21 receptor antagonists
BRPI0815797A2 (pt)	2015-06-16	Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
IL198542A0 (en)	2010-02-17	2-aminoquinolines as 5-ht(5a)receptor antagonists
EP2075252A4 (en)	2010-05-26	NK1 Receptor Antagonists COMPOSITION
IL195903A0 (en)	2009-09-01	Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
IL179485A0 (en)	2007-05-15	Indole-2 carboxamidine derivatives as nmda receptor antagonists
ZA201007904B (en)	2011-11-30	5-[-[2-(3,5-bis(trifluoromethyl)phenyl)-2-menthylpropanoylmethylamino]-4(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
IL209266A0 (en)	2011-01-31	Pyrrolidine derivatives as nk2 receptor antagonists
ZA201100841B (en)	2011-10-26	Novel compounds active as muscarinic receptor antagonists
IL207577A0 (en)	2010-12-30	Pyrrolidine ether derivatives as nk3 receptor antagonists
ZA200903499B (en)	2010-03-31	Indoles which act as via receptor antagonists
ZA201007519B (en)	2011-11-30	Spiro (piperidine-4, 2' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
ZA200903496B (en)	2010-03-31	Spiro-piperidine derivatives as via receptor antagonists
PL1912976T3 (pl)	2009-04-30	Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
IL185640A0 (en)	2008-01-06	Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
ZA201202150B (en)	2012-11-28	[1,4]-benzodiazepines as vasopressin v2 receptor antagonists